April 5, 2024
NOTICE TO ATTEND THE ANNUAL GENERAL MEETING
HELD ON MAY 8, 2024 IN ISOFOL MEDICAL AB (PUBL)
March 19, 2024
ISOFOL’S JAPANESE PARTNER SOLASIA INTENSIFIES ITS COMMITMENT TO THE CLINICAL DEVELOPMENT OF ARFOLITIXORIN
This website is intended for use by residents of Sweden only
About Isofol
Isofol Medical AB (publ) aims to raise the quality of life and increase the survival rate for patients with severe forms of cancer. The company’s drug candidate arfolitixorin is being developed with the purpose of increasing the efficacy of standard first-line treatment for several forms of solid tumours, including colorectal cancer. The next step in the clinical development program is currently being prepared based on a new dosage regimen that is expected to optimize arfolitixorin’s efficacy.
Isofol Medical AB (publ) is traded on Nasdaq Stockholm.
Upcoming Events
- May 08, 2024 - May 08, 2024
Interim report January-March 2024 - May 08, 2024 - May 08, 2024
Annual General Meeting 2024 - August 21, 2024 - August 21, 2024
Interim report January-June 2024
Media – Lates pressreleases
Isofol Medical AB (publ) publishes annual report and corporate governance report for 2023
GOTHENBURG, Sweden, April 16, 2024 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), today announced that the company’s annual report and corporate governance report…
Notice to attend the Annual General Meeting held on May 8, 2024 in Isofol Medical AB (publ)
GOTHENBURG, Sweden, April 5, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), hereby invites the shareholders of Isofol Medical AB (publ), Reg. No….
Isofol’s Japanese partner Solasia intensifies its commitment to the clinical development of arfolitixorin
GOTHENBURG, Sweden, March 19, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), (”Isofol”), today announces that the company’s collaboration partner, the Japanese pharmaceutical…
INVESTORS – latest reports and presentations
FOLLOW US
Stay updated on the latest news by
following Isofol on Linkedin.
